What the research shows: A phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity
Dihexa activates the c-Met receptor pathway, which is also involved in certain cancers creating a theoretical oncogenic concern
Experimental work examining angiogenic responses during muscle and tendon healing reported increased expression of angiogenesis-associated markers such as vascular endothelial growth factor (VEGF), CD34, and factor VIII within injured tissues following BPC-157 exposure [6]
These were sourced from donor patients and prostate cancer patients
Cycle length is typically 8 to 12 weeks, with physician reassessment before continuing
If ease of use matters most, the BPC spray is a great pick